Beckman Coulter reports that Cisbio has awarded its homogenous time-resolved fluorescence (HTRF) certification to the Paradigm detection platform
Cisbio's certification verifies that the detection platform meets or exceeds performance criteria for HTRF assays.
A new HTRF detection cartridge is now available for the unique, modular Paradigm platform, bringing the growing total selection to ten.
These detection cartridges can be interchanged in less than five minutes to meet different assay needs.
Paradigm, introduced earlier this year, is the first user-upgradeable and -configurable multimode reader.
It is described as ideal for labs with multiple users and applications.
The high-throughput detector reads on the fly, in formats from six to 1536 wells.
Cisbio's patented HTRF technology is incorporated into a growing selection of assays and reagents for drug discovery and screening.
These popular assays produce superior results and are easily miniaturised and automated.
"Beckman Coulter's application-focused, multifunctional detectors are very highly regarded and we are delighted that they have added an HTRF detection cartridge," commented Francois Degorce, head of HTRF marketing and business development at Cisbio.
"This partnership with Cisbio is a great example of the flexibility that makes Paradigm unique and successful," explained Jim Barry, marketing manager for Beckman Coulter.
"Detection modes are difficult and costly to add to other multimode detectors once the systems are installed.
"Our detection cartridge system maximises the users' return on investment and our instruments and automation platforms are already well-established in drug discovery and screening labs, where the use of TR-Fret assays, specifically HTRF are growing".
Cisbio is a developer of products and technologies used in nuclear medicine, in vitro diagnostics and assay development for drug screening procedures.
The company pioneered the field of homogenous fluorescence methodologies via its proprietary technology, HTRF, a highly sensitive, robust technology for the detection of molecular interactions and widely used by the pharmaceutical industry for the high-throughput screening stage of drug development.
In addition, Cisbio produces a selection of biological reagents and methods used by pharmaceutical and biotechnology companies, as well as contract research organisations (CROs).
